Russell Investments Group Ltd. Acquires 14,651 Shares of Adicet Bio, Inc. (NASDAQ:ACET)

Russell Investments Group Ltd. lifted its holdings in Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) by 15.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 109,740 shares of the company’s stock after purchasing an additional 14,651 shares during the quarter. Russell Investments Group Ltd. owned 0.26% of Adicet Bio worth $981,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Adicet Bio by 328.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,161 shares of the company’s stock worth $64,000 after purchasing an additional 5,489 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Adicet Bio by 16.9% in the third quarter. Bank of New York Mellon Corp now owns 134,491 shares of the company’s stock worth $1,913,000 after purchasing an additional 19,461 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Adicet Bio by 104.7% in the third quarter. Alliancebernstein L.P. now owns 26,400 shares of the company’s stock worth $375,000 after purchasing an additional 13,500 shares in the last quarter. State Street Corp lifted its position in shares of Adicet Bio by 311.5% in the third quarter. State Street Corp now owns 1,958,265 shares of the company’s stock worth $27,847,000 after purchasing an additional 1,482,409 shares in the last quarter. Finally, Algert Global LLC lifted its position in shares of Adicet Bio by 93.8% in the third quarter. Algert Global LLC now owns 32,190 shares of the company’s stock worth $458,000 after purchasing an additional 15,580 shares in the last quarter.

Adicet Bio Price Performance

NASDAQ:ACET opened at $5.53 on Friday. Adicet Bio, Inc. has a one year low of $5.13 and a one year high of $21.87. The company has a market cap of $237.57 million, a P/E ratio of -2.19 and a beta of 2.20. The firm’s fifty day moving average price is $6.10 and its two-hundred day moving average price is $9.37.

Adicet Bio (NASDAQ:ACET – Get Rating) last released its quarterly earnings data on Wednesday, March 15th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.16). As a group, equities research analysts expect that Adicet Bio, Inc. will post -2.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Adicet Bio in a research report on Thursday, May 18th. They set a “sell” rating on the stock. JMP Securities reaffirmed a “buy” rating and set a $19.00 price target on shares of Adicet Bio in a research report on Friday, March 17th. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Adicet Bio in a research report on Thursday, March 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Adicet Bio in a research report on Thursday, March 16th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.40.

About Adicet Bio

(Get Rating)

Adicet Bio, Inc is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf“ gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.